Transgene (TNG) Q3 2026 earnings summary

Executive summary

• TG4050 sustained 100% disease-free survival (DFS) after more than 3 years of follow-up in early-stage head and neck cancer; Phase 2 remains ongoing.

• TG4070 entered Phase 1 clinical development in resected non-small cell lung cancer (NSCLC), with five French sites open and recruiting.

• Cash and current financial assets of €84.3 million at September 30, 2026, support financial visibility through early 2028 under current plans.

Financial highlights

• 9M 2026 operating income was €4.3 million versus €6.1 million in 9M 2025; research tax credit contributed €3.9 million versus €5.8 million.

• Cash, cash equivalents and other current financial assets totaled €84.3 million at September 30, 2026, versus €111.9 million at December 31, 2025.

Outlook and guidance

• TG4050 Phase 2 immunological data expected by year end 2026, with presentation targeted for a 2027 scientific conference; topline results expected by end-Q1 2028.

• Phase 3-ready TG4050 manufacturing capacity targeted by end-2027; scalable cell line-based manufacturing is in preparation.

• Current plans indicate sufficient cash for financial visibility until early 2028.